Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Conditions
Keywords
PCA, LPA, AD, Amnestic AD
Brief summary
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Interventions
DRUGF-18 AV 1451
Tau binding agent
DRUGC-11 PiB
Amyloid binding agent
Sponsors
Mayo Clinic
National Institute on Aging (NIA)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Over the age of 21 * Must have an informant who will be able to provide independent evaluation of functioning * English is primary language * All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). * All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language * All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain
Exclusion criteria
* If you have had a stroke or tumor that could explain your symptoms * Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study * Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded * Subjects will be excluded if they have poor vision (20/400) * Women that are pregnant or post-partum and breast-feeding will be excluded * Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). | 5 years |
| Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Rates of change in amyloid-PET burden over time. | baseline, 1 year |
| Rates of change in tau-PET burden over time. | baseline, 1 year |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJennifer Whitwell, Ph.D.
Mayo Clinic
Outcome results
None listed